Combination serotonin specific reuptake inhibitor and serotonin 1A receptor partial agonist for reducing L-DOPA-induced dyskinesia

US12285426B2 · kind B2 · utility

Assignees

• The Research Foundation for The State University of New York · US
• Rosalind Franklin University of Medicine and Science · US
• BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY · US

Inventors

• Christopher Roy Bishop · Vestal, US
• Anthony West · Denver, US
• Fredric Manfredsson · Grand Rapids, US

Key dates

• Filing date: Apr 26, 2021
• Grant date: Apr 29, 2025
• Expiry date: Sep 28, 2043

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/16
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating and attenuating L-DOPA-induced dyskinesia, comprising administering an effective dose of at least one pharmacological agent, e.g., vilazodone, having serotonin-specific reuptake inhibition (SSRI) and serotonin receptor 1A (5-HT1AR) partial agonism activity, in conjunction with L-DOPA. Other agents, such as an L-DOPA decarboxylase inhibitor, e.g., carbidopa, or other adjunct treatments may also be provided.